2022 World Conference on Lung Cancer (ePosters)-EP16.03-009. Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping

EP16.03-009. Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping

Back to course

Pdf Summary

This study aimed to investigate KEAP1 genomic alterations (GAs) in advanced non-small cell lung cancer (aNSCLC) using a liquid biopsy. KEAP1 mutations have been associated with oncogenesis and drug resistance in solid tumors. The study found that KEAP1 mutations were identified at similar rates in advanced NSCLC patients using plasma-based testing, regardless of clinical status. This suggests that plasma-based testing can expedite the identification of KEAP1 mutations and help identify patients for clinical trials.<br /><br />The study also looked at the co-occurrence of KEAP1 mutations with other biomarkers. It found that KEAP1mut patients did not have different rates of biomarker co-occurrence based on STK11 status. This suggests that the impact of KEAP1 on treatment outcomes can be investigated independently of STK11 status.<br /><br />The study also highlighted the clinical relevance of KEAP1 in aNSCLC, particularly for KRAS non-G12C alterations. The frequency of KRAS non-G12C alterations in KEAP1mut patients was similar to that of KRAS G12C. This suggests that further investigation is needed to understand the role of KEAP1 in KRAS non-G12C aNSCLC.<br /><br />The study analyzed genomic results from NSCLC patients who underwent liquid biopsy testing. It found that 3.7% of the patients had KEAP1 mutations. The majority of these patients had adenocarcinoma, were newly diagnosed, and had a median tumor mutational burden (TMB) of 18.78 mut/Mb.<br /><br />Further analysis revealed that 50% of KEAP1mut patients had co-occurring alterations in other biomarkers for NSCLC. This indicates the complexity of the genomic landscape in aNSCLC and the need for a comprehensive approach to biomarker testing.<br /><br />Overall, this study provides insights into the prevalence and clinical relevance of KEAP1 mutations in advanced NSCLC. The findings highlight the importance of plasma-based genomic testing in identifying and characterizing these mutations, as well as their implications for treatment and clinical trial eligibility.

Asset Subtitle

Dwight H Owen

Meta Tag

Speaker Dwight H Owen

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

KEAP1 genomic alterations

advanced non-small cell lung cancer

liquid biopsy

oncogenesis

drug resistance

plasma-based testing

clinical trials

biomarker co-occurrence

STK11 status

KRAS non-G12C alterations